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Abstract 
This study measures the different types of vulnerability experienced by Bangladeshi pharmaceutical firms since 2005, 
consequent upon the Agreement on Trade Related Intellectual Property Rights (TRIPS) of the World Trade Organisation 
(WTO). We find that that R&D-related vulnerability was the highest in the pharmaceutical sector in Bangladesh. Cluster 
analysis supports this proposition as 79.8% of the sampled firms had below average levels of innovativeness. We argue 
that the TRIPS transition period (which began in 2005 and is to end in 2015) has not been used effectively used by Bang-
ladesh, the most technologically advanced LDC to create a strong technological platform for the pharmaceutical industry. 
Also, the expected process of transfer of technology has not taken place. We recommend that the post-TRIPS industrial 
policy for the pharmaceutical industry in Bangladesh should be designed and delivered with a key focus to improve the 
R&D and innovation capabilities of the domestic firms. Moreover, the WTO must evaluate the current mechanisms un-
derpinning developed countries-LDCs technology transfer. 
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1. Introduction 
The Agreement on Trade Related Intellectual Property Rights (TRIPS) of the World Trade Organisation 
(WTO) has provided special consideration to the least developed countries (LDCs), including Bangladesh, by 
allowing an extended transition period for 10 years (beginning from 2005). Nevertheless, they are obliged to 
implement a strict patent regime on the 1 January 2016. As mentioned in the TRIPS Preamble as well as in 
Article 66.2, the WTO has also instructed its developed country members to transfer technology to LDCs 
enabling them ‘to create a sound a viable technological base’. Interestingly, many scholars are apprehensive of 
the implementation of Article 66.2 and are critical of the effectiveness of the current monitoring mechanism of 
the WTO. They believe that the treaty will rather thwart the growth of the pharmaceutical industry in many 
countries (Correa 2007; Chaudhuri 2007; Danzon 2007; Artz et al. 2010; Abbott 2011;  Moon 2011).  
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Under a protective regulatory regime, the Bangladeshi pharmaceutical industry has made considerable 
progress since 1982. Over 95% of the local demand for medicines is met by domestic firms and medicines are 
exported to about 80 countries (BAPI Annual Report 2012). It is argued that in the context of an integrated 
global economy, the implementation of this multilateral trade-related treaty in developing countries in 2005 
has since then had the potential to affect the growth of the pharmaceutical industry in LDCs (the spillover 
effects of stronger IP protection) (Yu 2009; Abbott 2012).   
 
In this study, we have measured the different types of vulnerability facing Bangladeshi firms to the TRIPS 
Agreement since 2005 to see which type of vulnerability (negative impact) is the most important and warrants 
immediate intervention. A cluster analysis has helped us to identify two clusters of firms based on their degree 
of different types of vulnerability. We have found that the cluster of firms with a higher degree of 
vulnerability to the TRIPS Agreement has a lower level of innovativeness and vice versa. Thus, our findings, 
in addition to providing key insights into how the post-TRIPS industrial policy for the pharmaceutical industry 
in Bangladesh should be designed and delivered, also have important implications for other LDCs. Moreover, 
these findings can be used by the WTO to evaluate the current mechanism related to developed countries-
LDCs technology transfer, and to review its TRIPS-related considerations for LDCs. 
2. Theoretical framework  
2.1. The Post TRIPS-regulatory transition and innovation 
The TRIPS Agreement does not only involve regime shifting, but it has also triggered firm level changes in 
technical expertise and innovation to maintain competitiveness. According to Van Den Bergh (2007), 
evolutionary economics view of technical change is the most appropriate theoretical framework for the study 
of transitions and innovations. In the evolutionary economics, firm level innovation efforts involving changes 
in routine activities and the observed path dependency are studied concurrently (Coombs & Hull 1998). ‘Path 
dependency’ means that in the absence of a supportive technological regime, in response to unfavourable 
changes in the surrounding environment, a firm’s change in routine (adaptation strategy) is based on its own 
path and history. Therefore, a firm’s future technological change or dynamic capability depends on its past 
technological change, and the firm level technological change is cumulative in nature (Nelson & Winter 
2002). Therefore, it is important to know that in the absence of any supportive technological regime, what 
adaptive strategies Bangladeshi pharmaceutical firms are adopting through bringing necessary changes in their 
routine in the areas where they are more vulnerable, and what sort of innovative efforts have individual firms 
begun, which will be augmented in the future to comply with the TRIPS Agreement. 
2.2. Measuring the post-TRIPS vulnerability of pharmaceutical firms 
 Although, in the economics literature, the TRIPS Agreement has been widely viewed as a source of 
uncertainty for the developing world (Danzon 2007; Abbott 2011; Yu 2011; Sampath 2012), there is no 
available empirical literature on measuring the vulnerability of an industrial sector in a LDC setting facing 
such a major regulatory change. Also, the quantification of vulnerability is a challenging task.  However, the 
climate change literature is useful in understanding the methodological techniques used to measure 
vulnerability. Heltberg and Bonch-Osmolovskiy (2011) view vulnerability is ‘a function of the risks, exposure 
and sensitivity to risks, and adaptive capacity’ (p.5). As outlined by McCarthy et al. (2001), ‘exposure’ can be 
considered as a direct hazard or stressor, and ‘sensitivity’ refers to the degree of response to the hazard. Thus, 
the potential impact depends on exposure and sensitivity. McCarthy et al. (2001, p.8) have defined 
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adaptability as ‘a function of wealth, technology, education, information, skills, infrastructure, access to 
resources, and stability and management capabilities’. Brooks (2003) terms adaptive capacity as ‘the ability or 
capacity of a system to modify or change its characteristics or behaviour so as to cope better with existing or 
anticipated external stresses’ (p.8). In this study, the conceptual framework for the post-TRIPS industrial 
vulnerability is based on the following relationship (Füssel and Klein 2006; Gbetibouo and Ringler 2009): 
 
Vulnerability (V) = Potential impact (I) – Adaptive actions (A)                                                                  (1) 
3. Research methodology 
3.1. Choice of variables for measuring vulnerability 
A review of the recent literature suggests that the TRIPS Agreement is discriminatory to poor countries. 
Kanwar & Evenson (2003) studied the impact of stronger IP protection on research and development (R&D) 
spending in 85 countries, and found that unless a a stronger IP regime did not encourage innovation activities 
in poor countries. In general, some potential sources for concern for poor countries include unequal 
bargaining power; the resurgence of MNCs in the domestic market; increased price of raw materials and 
technology; increased imports of medicines; fall in the competitiveness of small firms  (Kuanpoth 2006; 
Wendt 2007; Li 2008; Guzmán 2012; Kapczynski & Hall 2009; Yu 2011).  
 
The development of technology and the manufacturing pharmaceutical raw materials, especially active 
pharmaceutical ingredients (APIs), requires high levels of engineering and chemistry skills, which are largely 
absent in LDCs including Bangladesh and thus pharmaceutical firms mostly depend on imported raw 
materials (Sampath 2007). In LDCs, most technologies are imported; however, increased imports are unlikely 
to result in technology transfer into countries with weaker absorptive capacity (Acharya & Keller 2009; Yang 
& Maskus 2009).  
 
Currently, governments across countries insist that imported medicines should be produced following the 
WHO’s current good manufacturing practices (cGMPs) guidelines (Bah-Traore 2012). Therefore, a higher 
regulation handling capability is more important than before for firms interested in export. In the post-TRIPS 
period, a large number of Indian pharmaceutical firms have adopted R&D-intensive business models to 
improve their regulation handling capability; currently, there are more than 100 Indian pharmaceutical firms 
with USFDA accreditation (Arora et al. 2008; Guennif & Ramani 2010). Unfortunately, to date, there is no 
pharmaceutical company in Bangladesh with USFDA accreditation. In the Bangladeshi pharmaceutical sector, 
R&D investments and the number of R&D personnel are much lower than in Indian firms; average annual 
R&D spending as a percentage of sales is only 1% (in India 7%), while the average R&D staff employed as a 
percentage of the total number of the employees is below 1% (in India the figure is around 5%) (Sampath 
2007). Therefore, in export markets, Bangladeshi pharmaceutical firms face strong competition from the 
MNCs as well as from pharmaceutical firms in China, but the main threat is from Indian firms. 
 
Table 1 provides a list of six types of vulnerability, the potential impacts of the TRIPS Agreement and the 
adaptive actions undertaken to minimize those impacts which have been supported by current literature on the 
TRIPS Agreement  (Hati 2006; Mani 2006; Chaudhuri 2007; Pradhan 2007; Wendt 2007; Chittoor et al. 2008; 
Li 2008;; Rai 2009; Guennif & Ramani 2010; Basant 2011;  Nielsen et al. 2011). A positive (+) sign after 
each potential impact variable (IV) indicates the expectation of a positive functional relationship with 
vulnerability and a negative (−) sign indicates inverse functional relationship. 
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Table 1. Types of TRIPS-related vulnerability and related impact variables (IVs) and adaptive action sub-variables (AVs)  
              
Types of Vulnerabil-
ity 
Impact vari-
ables (IVs) 
Adaptive action sub-variables   (AVs) 
 
Raw materials-
related vulnerability 
(V1) 
 
IV1: Difficulty 
in obtaining raw 
materials from 
abroad (+) 
 
AV11: Strategic partnership with raw material suppliers from abroad (−) 
AV12: Upstream vertical integration (merger/acquisition) with overseas raw material 
suppliers (−) 
AV13: Increasing investment in in-house production of raw materials (−) 
AV14: Using substitute ingredients for some drugs (−) 
 
Technology-related 
vulnerability (V2) 
IV2: Difficulty 
in obtaining the 
latest technolo-
gies (+) 
AV21: Increased investment in developing own technological capabilities (−) 
AV22: Technology collaboration with domestic firms (−) 
AV23: Technology collaboration with foreign  firms/licensing technology (−) 
AV24: Obtaining technology through licensing agreement(s) with foreign  firms (−) 
 
Quality and regula-
tory compliance-
related vulnerability 
(V3) 
IV3: Conformity 
to higher quality 
and regulatory 
standards  (+) 
AV31: Increased investment to improve quality (−) 
AV32 : Employing highly skilled/scientific workforce from home or overseas (−) 
 AV33 : Increasing investment in on-the-job training (−) 
   
 
R&D-related  
vulnerability (V4) 
 
 
IV4: Higher 
investment 
required in 
R&D and inno-
vation activities 
(+) 
 
AV41: Raising venture capital or debt finance (−) 
AV42: Access to government R&D support funds (−) 
AV43: Joint R&D activities with public/private research institutes/universities (−) 
AV44: R&D collaboration with foreign firms/MNCs/ international organisations (−) 
 
 
Domestic 
competition-related  
vulnerability (V5) 
 
IV5: Increased 
competition 
from MNCs and 
imports in the 
domestic mar-
ket (+) 
AV51: Downstream vertical integration to access more distribution channels (−) 
AV52: Strategic partnerships with domestic customers, e.g. private/public hospitals, 
public organisations/NGOs (−) 
AV53: Undertaking cost-reduction programs (−) 
AV54: Expanding production capacity and product range(−) 
AV55: Increasing investment in market promotion (−) 
AV56: Building strategic alliances with foreign firms and MNCs (e.g. contract 
manufacturing) (−) 
AV57: Obtaining ‘compulsory licences’ from the government to produce on-patent drugs 
under legal cover (−) 
 
International 
competitiveness-
related  vulnerability 
(V6) 
IV6: Increased 
competition 
from the MNCs 
and foreign 
firms in the 
export market 
(+) 
AV61: Obtaining accreditation from developed countries (e.g. USFDA, UKMHRA, 
TGA) (−) 
AV62: Developing niche market strategies (focusing on essential drugs, drugs for ne-
glected diseases, and herbal products) (−) 
AV63: Establishing extensive sales and distribution networks abroad (−) 
AV64: Strategic partnerships with customers abroad (e.g. hospitals, NGOs and interna-
tional organisations) (−) 
AV65: Entering into joint ventures with foreign companies (−) 
3.2. Choice of variables for measuring the innovativeness of  firms 
The term ‘innovativeness’ refers to a firm’s dynamic capability, which is measured in two ways: firstly, in 
terms of inputs, such as annual R&D expenditure/R&D intensity and in terms of output, such as the number 
new products introduced in a year, product diversity and the number of patents (Hollenstein 1996; Damanpour 
2010). In addition, a firm’s innovativeness has been found to be correlated with its size (Pla- Barber & Alegre 
2007). Accordingly, given the availability of the relevant data, in this study a Bangladeshi pharmaceutical 
firm’s innovativeness is measured using the following conceptual framework: 
 
Innovativeness = f (firm size, product introduction, product diversity, market focus, export success)       (2) 
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Table 2 provides a list of ordered categorical variables used in this study to measure innovativeness. 
               Table 2.  Innovation variables used in calculating the innovativeness indices of Bangladeshi pharmaceutical firms. 
Innovation variable Proxy variables 
Firm size The number of employees; the number of finished products 
Product introduction The average number of new products introduced by the company annually 
Product diversity Whether a firm is a finished product manufacturer, raw material producer or both; Whether 
a firm produces herbal products;  Whether a firm produces  animal products 
Market focus Whether a firm focuses mainly on the domestic market, foreign markets or equally both 
Export success Whether a firm has no plan to export soon, is going to export soon, exports occasionally or 
exports regularly; The number of export destinations 
3.3. Multivariate analysis to assess construct validity of sub-variables 
To establish the validity of the measurement procedure (construct validity) and to get rid of less important 
(redundant) variables in measuring different types of vulnerability facing firms and their innovativeness, we 
used a widely acceptable multivariate statistical analysis technique for the reliability analysis, called 
Cronbach’s Alpha.  Cronbach’s Alpha is the average correlation co-efficient of each of the variables 
belonging to an underlying factor, which is widely used to develop composite indices through simple 
arithmetic averaging (Cooksey 2007; Field 2009). Generally, the minimum acceptable value of Cronbach’s 
alpha is expected to be 0.7 (internal consistency reliability is 70%); however in the literature, with low 
number of variables, 0.5 is considered to be the minimum acceptable number (George & Mallery 2003).  
3.4. Data collection 
 The population to be surveyed is the 149 member firms of the Bangladesh Association of Pharmaceutical 
Industries (BAPI) as listed in the BAPI Annual Report (2010). The data for this study were collected between 
October and December 2012 from the owners/ high level managers of these firms through a self-administered 
questionnaire. A total of 94 completed questionnaires were obtained. The perception survey questionnaire 
measured six types of impact variables and their corresponding adaptive capacity variables using a five-point 
closed order Likert scale, where 1 indicates that the variable is not important at all and 5 is very important. 
Also, demographic and general information was sought to measure innovativeness of firms.  
3.5. Measuring vulnerability and innovativeness using indices 
In this study, six types of vulnerability to the TRIPS Agreement facing the sampled Bangladeshi 
pharmaceutical firms as well as their innovativeness were measured through six composite indices. A 
composite index is obtained from compiling a set of related variables (Nardo et al. 2005).A composite index 
representing a firm’s certain type of vulnerability (e.g. vulnerability related to raw materials) has been created 
using two variables, i.e. one impact variable and one adaptive capacity variable (average of the adaptive 
capacity sub-variables). The vulnerability index has taken values between 0 and 1 where 0 indicates no 
vulnerability and 1 indicates extreme vulnerability.  
 
In recent decades, composite indices have been increasingly used for comparing country performance in 
terms of human development, competitiveness, sustainability and industrialization and to divide them into 
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various groups or clusters (Nardo et al. 2005). For example, Guillaumont (2007) has used a structural 
economic vulnerability index (EVI) to determine which countries can be labelled as LDCs.  
 
Based on the methodology developed by the UNDP in constructing a Human Development Index (HDI), to 
develop composite indices, variable scores have been normalized (so that all values are between 0 and 1) 
(Anand & Sen 1994; Nardo et al. 2005). In line with the conceptual framework for calculating vulnerability, 
following the notable work of Anand & Sen (1994), the impact variables (with a positive functional 
relationship) and adaptive action variables (with a negative functional relationship0 have been normalized 
using the following formulae 3 and 4,  where IV*ij is the standardized score of impact variable (IV) i of firm j ( 
the higher the value of  IV*ij, the higher is the vulnerability) and AV*ij is the standardized score of aggregate 
adaptive action variable (AV) i of firm j (the higher the value of  AV*ij, the lower is the vulnerability). 
* ( )
( ) ( )
ij i
ij
i i
IV Min IV
IV
Max IV Min IV
    (3) 
      . *
( )
( ) ( )
i ij
ij
i i
Max AV AV
AV
AV AVMax Min
                                                                           (4) 
      Given the absence of any reliable weighing methods of the sub-variables, in most cases composite indices 
are obtained by calculating an un-weighted average of the constituent variables ((Anand & Sen 1994; Nardo 
et al. 2005; Patnaik & Narayanan 2009). The composite index (Vij) of an individual firm j for a particular type 
of vulnerability i has been calculated with the formula 5 where, IV*ij is the standardized score of impact 
variable (IV) and AV*ij is the standardized score of the average of adaptive action sub-variables (AV) of firm j. 
* *
2
ij ij
ij
IV AV
V
   (5) 
      Finally, different types of vulnerability across the sector (Vsi ) have been determined from the following 
equations,  where Vij is the composite index of an individual firm j for a particular type of vulnerability i: 
ij
s
i
V
V
j
 
¦
  (6) 
Following Hollenstein (1996), first, the composite innovativeness index of a firm j (INNOVcj) has been 
obtained using the following equation 7, where X*1j to X*1j are the standardized N retained variables of firm j 
obtained through the reliability analysis (Cronbach’s alpha) and then each firm’s innovativeness index has 
been expressed using Z-scores with a mean value of 0 and standard deviation of so that firms can be classified 
as below (<0) and above average (>0) in relation to innovativeness. 
 
  INNOVcj = (X*1j + X*2j +….. + X*Nj)/N                                                                              (7)          
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3.6. The use of the vulnerability and innovativeness indices and other statistical techniques 
In this study, first, the mean values of the different types of vulnerability indices across the sector have 
been compared to see which type of vulnerability is the highest. Second, one-way repeated measures ANOVA 
was performed to examine whether the individual differences of firms in the degree of different types of 
vulnerability was statistically significant. Third, a two-step cluster analysis was performed to classify firms 
into groups according to various levels of vulnerability. Finally, a one-way ANOVA was performed to see 
whether the mean values of various clusters are different from each other in terms of different types of 
vulnerability. 
4. Empirical results 
In this study, the data were analysed in a number of stages using SPSS. Cronbach’s alpha value for the 
items included in the different types of vulnerability indices were 0.564, 0.767, 0.723, 0.697, 0.718 and 0.828 
respectively. Although the value 0.564 (related to raw-material related vulnerability) was low it is acceptable 
for two reasons: first, the number of variables is only three and the minimum corrected item-total correlation 
was 0.397, which indicates that the items form a reliable scale (Field 2009). However, Cronbach’s alpha for 
the innovativeness index sub-variables was 0.834, which indicates a high level of consistency and reliability 
of the innovativeness scale; 5 out of 9 original sub-variables were retained to obtain the highest alpha value. 
  
Next, following equation 3 to 6, six types of vulnerability indices across the sector were calculated.  The 
mean value and the standard deviation of the different types of vulnerability are shown in Table 3 in terms of 
their importance. 
 
      Table 3. The mean and standard deviation of different types of vulnerability 
 
Type of vulnerability Mean Standard deviation 
R&D-related  vulnerability (V4) 0.8722 0. 1364 
International competitiveness-related  vulnerability (V6) 0.7848 0.1491 
Raw materials-related vulnerability (V1) 0.6831 0.1725 
Technology-related vulnerability (V2) 0.6817 0.2007 
Quality and regulatory compliance-related vulnerability (V3) 0.5790 0.1135 
Domestic competition-related  vulnerability (V5) 0.2770 0.1364 
 
Table 3 shows that the R&D-related vulnerability (V4) is the most important type of vulnerability (0.8722) 
facing the Bangladeshi pharmaceutical firms followed by international competitiveness-related vulnerability 
(V6) with the  value of 0.7848, where 0 indicates no vulnerability and 1 indicates full vulnerability. However, 
the least important type of vulnerability is the domestic competition-related vulnerability (V5) with the value 
0.2770. 
 
One-way repeated measures ANOVA indicated that there was a significant difference between firms  in the 
degree of three types of vulnerability, namely R&D-related vulnerability, international competitiveness-
related vulnerability and quality and regulatory-related vulnerability, F(4, 372) = 71.789, p<.001. Machly’s 
test for sphericity was not violated (p>.094), thus the result of the one-way repeated measures ANOVA test is 
highly reliable. Moreover, a two-step cluster analysis was used to classify the sampled firms in terms of their 
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innovativeness scores and the overall vulnerability scores. Two clusters were obtained (Figure 2). Cluster one 
comprised 17 firms (18.1%) and cluster two comprised 77 firms (81.9%). Finally, a one-way ANOVA 
indicated that there was a significant difference in terms of innovativeness and various types of vulnerability 
between the members of the two clusters except for in terms of domestic competition-related vulnerability. 
The test results are F (1, 92) = 18.24, p<0.05; F (1, 92) = 59.16, p<0.05; F (1, 92) = 96.71, p<0.05; F (1, 92) 
= 8.11, p<0.05; F (1, 92) = 36.20, p<0.05; F (1, 92) = 0.85, p>0.05; and F (1, 92) = 55.48, p<0.05. Table 4 
illustrates how the firms in each of the two clusters differ in terms of vulnerability, innovativeness and 
demographic characteristics.  
 
Table 4. Between-clusters differences for vulnerability and innovativeness measures and in terms of 
demographic characteristics  
 
 Cluster one (17 firms; 18.1% of the  total 94 firms) Cluster two (77 firms; 81.9% of the  total 94 firms) 
Mean vulnerability score V1 V2 V3 V4 V5 V6 V1 V2 V3 V4 V5 V6 
 0.46 0.38 0.51 0.72 0.26 0.59 0.73 0.75 0.59 0.91 0.28 0.83 
Standard deviation 0.1385 0.2022 0.0772 0.1678 0.1839 0.1256 0.0152 0.0142 0.0131 0.0116 0.0222 0.0133 
 
Average innovativeness 
index 
 
0.68 -0.15 
Age more than 10 years 88.24% (15 out of 17 firms) 62.34% (48 out of 77 firms) 
 
No. of employees more 
than 1000 
 
82.35% (14 firms) 24.68% (19 firms) 
No. of finished products 
250 and above 
52.94% (9 firms) 11.69% (9 firms) 
Producing raw-materials 17.65%  (3 firms) 6.49% (5 firms) 
 
Producing herbal drugs  11.76% (2 firms) 19.485 (15 firms) 
Producing vet products 47.06% (8 firms) 23.38% (18 firms) 
 
Focusing on only domestic 
market 
52.94% (9 firms) 71.42% (55 firms) 
Focusing on both domestic 
and export markets 
 
47.06% (8 firms) 25.97% (20 firms) 
Exports regularly 64.71% (11 firms) 32.47% (25 firms) 
 
Exported to more than 10 
countries in 2011  
 
52.94% (9 firms) 7.79% (6 firms) 
5. Discussion, conclusions and policy implications 
     The empirical results in this study have a number of policy implications. It was found that the R&D-related 
vulnerability was the highest across the pharmaceutical sector in Bangladesh (0.8722) followed by 
international competitiveness-related vulnerability (0.7848). If 0 indicates that the vulnerability is nil and 1 is 
the highest, this points to the fact that Bangladeshi pharmaceutical firms have not been able to develop 
considerable technical and scientific capability as well as a higher level of regulation handling capability. The 
cluster analysis supports this proposition as only 18.1% of the sampled firms have an above average level of 
innovativeness (mean is 0.68). As the innovativeness indices are expressed as z-scores, the value 0.68 
indicates that even in cluster one (the group with lower level of vulnerability than the other) only a few firms 
have satisfactory level of innovativeness. The mean values for R&D-related vulnerability and international 
competitiveness-related vulnerability of cluster one are 0.72 and 0.59 respectively, which indicate that unless 
they improve their R&D and innovation capacity as well as regulation handling capabilities, their 
competitiveness in domestic and export markets are likely to be negatively affected by the implementation of 
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the TRIPS Agreement in 2016. Conversely, cluster two includes 77 firms (81.9% of the sampled firms). The 
mean score for their innovativeness is -0.15; these firms have a below average level of innovativeness. They 
have a higher average level of vulnerability in all categories than those in cluster one. From Table 4, it can be 
deduced that the number of employees (the pharmaceutical sector mostly employs knowledge workers), 
product diversity and export performance are important determinants of firms’ adaptive capacity (to reduce 
vulnerability) as well as innovativeness.  
 
Finally, it can be argued that the TRIPS transition period has not been used effectively by the Bangladeshi 
pharmaceutical sector to create a strong technological platform for the industry and the expected process of 
transfer of technology has not taken place. The post-TRIPS industrial policy for the pharmaceutical industry 
in Bangladesh should be designed and delivered with a key focus on improving the R&D and innovation 
capabilities of the domestic firms. Moreover, the WTO should evaluate the current mechanisms related to 
developed countries-LDCs technology transfer, and should review its trade-related considerations for LDCs. 
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